Higher risk of hepatocellular carcinoma in Hispanic patients with hepatitis C cirrhosis and metabolic risk factors

被引:0
作者
Alina Wong
An Le
Mei-Hsuan Lee
Yu-Ju Lin
Pauline Nguyen
Sam Trinh
Hansen Dang
Mindie H. Nguyen
机构
[1] University of Washington,Division of Gastroenterology
[2] Stanford University Medical Center,Department of Medicine
[3] Stanford University Medical Center,Division of Gastroenterology and Hepatology
[4] National Yang-Ming University,Institute of Clinical Medicine
来源
Scientific Reports | / 8卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The effect of metabolic syndrome on chronic liver diseases other than non-alcoholic fatty liver disease has not been fully elucidated. Our goal was to evaluate if metabolic syndrome increased the risk of liver-related complications, specifically hepatocellular carcinoma (HCC) and decompensation, in cirrhotic chronic hepatitis C (CHC) patients. We conducted a retrospective cohort study of 3503 consecutive cirrhotic CHC patients seen at Stanford University from 1997–2015. HCC developed in 238 patients (8-year incidence 21%) and hepatic decompensation in 448 patients (8-year incidence 61%). The incidence of HCC and decompensation increased with Hispanic ethnicity, diabetes, and number of metabolic risk factors. Multivariate Cox regression analysis demonstrated that, independent of HCV therapy and cure and other background risks, Hispanic ethnicity with ≥2 metabolic risk factors significantly increased the risk of HCC and hepatic decompensation. There was no interaction between Hispanic ethnicity and metabolic risk factors. All in all, metabolic risk factors significantly increase the risk of liver-related complications in cirrhotic CHC patients, especially HCC among Hispanics. As the prevalence of metabolic syndrome increases globally, targeted health interventions are needed to help curb the effects of metabolic syndrome in CHC patients.
引用
收藏
相关论文
共 40 条
[11]  
Wong RJ(2008)Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus Hepatology 33 1554-134
[12]  
Gish RG(2001)Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States Hepatology 61 128-1364
[13]  
Chen Y(2012)Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3 Gut 33 1358-8130
[14]  
Wang X(2001)Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity Hepatology 81 8122-645
[15]  
Wang J(2007)Hepatitis C virus induces proteolytic cleavage of sterol regulatory element binding proteins and stimulates their phosphorylation via oxidative stress J Virol 61 636-1580
[16]  
Yan Z(2016)Diabetes Mellitus Increases Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Virus Patients: A Systematic Review Dig Dis Sci 111 1573-1751
[17]  
Luo J(2016)Diabetes Mellitus Heightens the Risk of Hepatocellular Carcinoma Except in Patients With Hepatitis C Cirrhosis Am J Gastroenterol 29 1743-326
[18]  
Ohki T(1999)Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways Hepatology 75 320-1415
[19]  
Arase Y(2007)Hepatitis C, metabolic syndrome, and inflammatory markers: results from the Third National Health and Nutrition Examination Survey [NHANES III] Diabetes Res Clin Pract 59 1410-1435
[20]  
Veldt BJ(2010)Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study Gut 109 1427-237